TSS
ENTA icon

Two Sigma Securities’s Enanta Pharmaceuticals ENTA Stock Holding History

Two Sigma Securities’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,022
Closed -$245K – 2721
2018
Q1 		$245K Buy
+3,022
New +$233K ﹤0.01% 2136

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Two Sigma Securities's ENTA Position: Q2 2018 in Review

Two Sigma Securities sold out of Enanta Pharmaceuticals (ENTA) in Q2 2018, closing a stake of 3,022 shares — an estimated $245K sold.

Two Sigma Securities first reported a position in ENTA in Q1 2018 and held it in 1 quarter. The position peaked at $245K in Q1 2018. 193 funds tracked by Wall St. Rank hold ENTA as of Q2 2018.

  • Two Sigma Securities reported no remaining Enanta Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Two Sigma Securities sold 3,022 Enanta Pharmaceuticals shares in Q2 2018, an estimated $245K.
  • Two Sigma Securities first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Two Sigma Securities's Enanta Pharmaceuticals position peaked at $245K in Q1 2018.
  • 193 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2018.

Based on Two Sigma Securities's 13F filing for Q2 2018, filed 14 Aug 2018.